Chimerix CEO M. Michelle Berrey to stand down as interim Office of Cheif Executive Officer is formed
February 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
The North Carolina-based biopharmaceutical company Chimerex has announced that Dr M. Michelle Berrey has resigned from her role as President …
Eisai and Purdue reveal positive Phase 3 data in insomnia
February 7, 2019Research and Development Eisai, Purdue Pharma, insomnia, lemborexant, pharma
Partners Eisai and Purdue Pharma have lifted the curtain on Phase 3 clinical data on their jointly developed therapy lemborexant …
Pharma chiefs will testify at Senate hearing on rising drug prices
February 7, 2019Sales and Marketing CEO, J&J, JJ, Pfizer, Sanofi, Senate, pharma, pricing
The Chief Executives of Pfizer, Sanofi and Bristol-Myers Squibb have said that they will join four other pharma execs in …
FDA approves first therapy for acquired thrombotic thrombocytopenic purpura: Sanofi’s Cablivi
February 7, 2019Sales and Marketing Calblivi, FDA, Sanofi, acquired thrombotic thrombocytopenic purpura, pharma
Following swiftly on the heels of the previous success with the announcement of positive Phase 3 data for Icaria in …
HIV drug holds hope for Alzheimer’s after significantly reducing inflammation in mice
February 7, 2019Research and Development HIV, dementia, inflamation
Lamivudine, a generic drug for HIV, significantly reduces age-related inflammation and other signs of aging in mice, according to a …
Pfizer ignores strike in Ireland as 900 employees’ pensions affected
February 7, 2019Business Services Ireland, Labour Court, Pfizer, cork, strike
US multinational Pfizer is going ahead with its decision to transfer 900 of its Irish employees into a new defined …
NICE joins forces with Canadian peer to offer scientific advice to the pharma industry
February 6, 2019Research and Development, Sales and Marketing CADTH, Canada, NICE, UK, pharma
NICE has announced a collaboration with its Canadian counterpart, the Canadian Agency for Drugs and Technology in Health (CADTH), with …
Sanofi’s Icaria combo extends progression-free survival in multiple myeloma at Phase 3
February 6, 2019Research and Development Icaria, Sanofi, multiple myeloma, pharma
Sanofi has continued to make progress in the development of Icaria (isatuximab), with the company announcing that the therapy met …
Genentech to develop ‘highly active cytokine’ with Xancor in deal worth $300m
February 6, 2019Research and Development Cancer, Genetech, IL-15 cytokine, Roche, Xancor, oncology
Roche’s Genentech unit has agreed to pay $120 million upfront as part of a research and licensing deal with California-based …
Takeda ordered to pay Bayer $155.19 million over patent infringement
February 6, 2019Research and Development Baxalta, Bayer, Nektar Therapeutics, Takeda, adynovate
A US court has ordered Takeda Pharmaceutical’s Baxalta unit to pay German firm Bayer AG $155.19 million for infringement of …
GSK buys Merck KGaA’s cancer immunotherapy for $4.2 billion
February 6, 2019Research and Development GSK, M7824, Merck, immunotherapy
British multinational GlaxoSmithKline has agreed to pay up to €3.7 billion ($4.2 billion) for the rights to Merck KGaA’s next …
Czech biotech SOTIO appoints experienced immune-oncology doc as new CMO
February 5, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Czech biotech SOTIO has announced the appointment of Dr Harald Fricke as the firm’s Chief Medical Officer (CMO). Dr Fricke, …
Former Ablynx exec joins Kiadis as Chief Scientific Officer
February 5, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ablynx, appointment, kiadis, pharma
Dutch/US firm Kiadis Pharma revealed that Dr Robert Friesen became its new Chief Science Officer (CSO) as January turned into …
Lilly’s Olumiant impresses in twin Phase 3 atopic dermatitis trials
February 5, 2019Manufacturing and Production, Research and Development Eli Lilly, Olumiant, atopic dermatitis, pharma
Eli Lilly has unveiled new Phase 3 data from two studies into the oral Janus kinase (JAK) inhibitor Olumiant (baricitinib). …
AstraZeneca scores accelerated approval in US and Europe for respiratory syncytial virus drug
February 5, 2019Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, EMA, FDA, MEDI8897, pharma, respiratory syncytial virus
It’s a double victory for AstraZeneca as the company announced its F monoclonal antibody MEDI8897 has been granted accelerated review …
More than 200 Xanax-related deaths in UK since 2015
February 5, 2019Manufacturing and Production Pfizer, UK, benzodiazepines, health, public health, xanax
There have been more than 200 deaths linked to misuse of the anti-anxiety drug Xanax in the UK since 2015. …
Reformulated OxyContin led to spike in Hepatitis C infections
February 5, 2019Manufacturing and Production OxyContin, USA, hepatitis C, heroin, infectious diseases, opioids
Efforts to create an “abuse deterrent” OxyContin pill inadvertently led to an increase in the number of Hepatitis C infections, …
Sanders calls on Catalyst pharma to justify $375,000 price tag for rare disease drug which was once free
February 5, 2019Manufacturing and Production Catalyst Pharmaceuticals, Jacobus Pharmaceuticals, Sanders, USA, pharma, pricing
Shares in Catalyst Pharmaceuticals plummeted Monday, after US Senator Bernie Sanders sent the firm a letter asking them to justify …
Alexander Hardy returns to Genentech as new CEO
February 4, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Genentech, appointment, pharma
Genetech, the biotech subsidiary of Swiss firm Roche, has named its new CEO, revealing that Alexander Hardy will be returning …
Positive CHMP recommendation for Sanofi’s atherosclerotic CVD drug Praluent
February 4, 2019Sales and Marketing Europe, atherosclerotic cardiovascular disease, cvd, pharma, praluent
It has been announced that Sanofi’s Praluent (alirocumab) has been awarded a positive recommendation from the European Medicines Agency’s Committee …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
